Sign In
Buy PTC
$139.72
-2.62 (-1.84%)
At Close: Jun 03, 2026
PTC, Microsoft & Volkswagen Collaborate on Codebeamer AI Copilot
09:30am, Thursday, 05'th Dec 2024
PTC partners with MSFT and Volkswagen for a Codebeamer AI Copilot designed to simplify product development.
PTC Partners with Microsoft and Volkswagen Group to Develop Codebeamer Generative AI Copilot
08:30am, Tuesday, 03'rd Dec 2024
Collaboration brings together industry leaders to advance generative AI use cases for manufacturing Codebeamer Copilot expected to simplify requirements management as part of the product development p
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
01:50pm, Monday, 02'nd Dec 2024
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
12:58pm, Monday, 02'nd Dec 2024
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecul
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
09:32am, Monday, 02'nd Dec 2024
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
07:14am, Monday, 02'nd Dec 2024
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological diso
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
07:00am, Monday, 02'nd Dec 2024
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalt
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
07:00am, Wednesday, 27'th Nov 2024
WARREN, N.J. , Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV
PTC Therapeutics discontinues development of ALS drug after trial failure
04:41pm, Tuesday, 26'th Nov 2024
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
04:30pm, Tuesday, 26'th Nov 2024
- Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J. , Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-con
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 25'th Nov 2024
WARREN, N.J. , Nov. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 20, 2024, the company approved non-statutory stock options to purchase an aggregate of 1
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
04:14am, Thursday, 21'st Nov 2024
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
06:09pm, Wednesday, 13'th Nov 2024
The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wedn
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
06:02pm, Wednesday, 13'th Nov 2024
- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - PTC pioneers new approach for CNS dr
